论文部分内容阅读
通过国际原子能机构支持的多中心协作，８０例癌性骨痛患者接受单次１５３Ｓｍ－ＥＤＴＭＰ注射，观察单次注射两种不同剂量３７ＧＢｑ／ｇ或１８．５ＧＢｑ／ｇ对癌性骨痛治疗的效果及副作用。以止痛剂用量变化、主观止痛感觉、局部功能改进、化验等临床指标，连续观察１６周。除７例病人在观察期间死亡外，７３例存活者中，止痛有效率８６．３％；两种剂量的止痛效果、止痛时间、副作用类型及程度等指标一致；用药后疗效持续时间（８．２±４．５）周；５０％病例有血相改变，１０例有肝功改变；副作用均在４－６周内恢复；１０例止痛无效，其中９例为男性，６例肺癌。结果证实单次１５３Ｓｍ－ＥＤＴＭＰ注射是有效的骨痛姑息治疗技术；但对终晚期或伴其他组织转移病例，没有根本性改善作用；止痛疗效与副作用均与剂量无关；男性、肺癌病例治疗无效可能性大。用１５３Ｓｍ－ＥＤＴＭＰ治疗癌性骨痛，确实需要进一步客观、科学评价。
Through IAEA-supported multi-center collaboration, 80 patients with cancerous bone pain received a single injection of 153Sm-EDTMP and observed the effect of a single injection of two different doses of 37 GBq/g or 18.5 GBq/g on cancer pain. And side effects. Changes in the amount of analgesic, subjective analgesic sensation, local function improvement, laboratory tests and other clinical indicators were continuously observed for 16 weeks. Except for 7 patients who died during the observation period, the effective rate of analgesia was 86.3% in 73 survivors; the analgesic effect, analgesia time, type and degree of side effects were consistent with the two doses; the duration of efficacy was after administration (8.8%). 2 ± 4.5) weeks; 50% of cases had blood changes, 10 cases had liver function changes; side effects were restored within 4-6 weeks; 10 cases of pain relief, of which 9 cases were male and 6 cases of lung cancer. The results confirmed that a single injection of 153Sm-EDTMP was an effective palliative treatment for bone pain; however, there was no fundamental improvement in patients with advanced or late metastases; the analgesic efficacy and side effects were independent of the dose; male and lung cancer cases were ineffective. Great sex. Treatment of cancerous bone pain with 153Sm-EDTMP does require further objective and scientific evaluation.